Background The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire-sponsored, international, observational
Introduction
Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is a rare disease characterized by recurrent and unpredictable swellings, most commonly of the subcutaneous tissues of the skin, face and extremities and mucosa of the gastrointestinal tract. 1, 2 Attacks may share a clinical presentation with a range of more common diseases, which can lead to delayed or missed diagnosis; and while the majority of untreated attacks resolve within a few days, attacks localized to the larynx can be fatal if immediate treatment is not provided. 3 The recently updated and revised World Allergy Organization and European Academy of Allergy and Clinical Immunology guideline for HAE advocates the need for acute on-demand therapies to be made available for patients with HAE-C1-INH. 4 This is also supported by several international and regional consensus documents. 5 Icatibant, a bradykinin B2 receptor antagonist, was approved in the EU in 2008 for the acute treatment of HAE attacks, based upon efficacy and safety data in adults with HAE-CI-INH from two phase III randomized controlled trials. 6 Subsequently, in 2011, based on data from a phase IIIb open-label study, 7 approval was extended to self-administration. The Icatibant Outcome Survey (IOS) is an international, prospective, observational study (NCT01034969) established in 2009. Data from the IOS have clearly shown that early icatibant treatment results in earlier resolution of attacks 8 and that real-world outcomes of icatibant are comparable with the aforementioned controlled studies. 9 More recently, a range of IOS publications have further described icatibant use and disease characteristics for HAE-C1-INH patients in the real-world setting across the IOS countries. [10] [11] [12] [13] [14] [15] A recent country-specific IOS analysis, using 2015 data, clearly identified German patients with HAE-C1-INH who are enrolled in IOS administer icatibant to treat their attacks significantly earlier, following symptom onset, than similarly diagnosed IOS patients from Austria, France, Italy, Spain, and the United Kingdom.
14 Here, we report data from IOS that focus on icatibant treatment outcomes in patients with HAE-C1-INH from seven HAE specialist centres across Germany and compares outcomes with patients from 11 other IOS countries.
Patients and methods
Study design and patients Age at IOS enrolment, years n (missing)
37 (0) 25 (0) 11 (0) 7 (0) 6 (0) 4 (0) 3 (0) Median ( Age at first symptoms, years n (missing)
34 (3) 17 (8) 11 (0) 6 (1) 5 (1) 4 (0) 2 (1) Median ( Age at diagnosis, years n (missing)
36 (1) 22 (3) 11 (0) 7 (0) 6 (0) 4 (0) 3 (0) Median ( Delay in diagnosis, years n (missing)
34 (3) 17 (8) 11 (0) 6 (1) 5 (1) 4 (0) 2 (1) Median ( 
Results

IOS patients in Germany report significantly fewer severe attacks
German patients were significantly less likely than patients from other countries to report severe or very severe attacks (38.7% vs. 57.5%, respectively; P < 0.001; Fig. 1 ).
Patient demographics and baseline characteristics are comparable between Germany and other countries
Overall, the German IOS cohort did not differ significantly from the comparator cohort (Table 1 ) with respect to sex or diagnosis. Similarly, no differences were noted in the anatomic location of attacks (data not shown). The variations of several of these parameters across German centres are described in Table 2 .
IOS patients in Germany treat their attacks with icatibant significantly earlier
Overall, time to treatment with icatibant, time to resolution and duration of attack were all significantly shorter in the German group compared with other IOS countries (all P < 0.0001; Table 3 ). Using a generalized mixed model for repeated measures, a significant difference in attack duration was observed between patients in Germany and patients from other IOS countries ( Fig. 2 ; P = 0.0227). The earlier treatment of German patients can be appreciated in Fig. 3 , which shows duration of attack vs. timing of icatibant administration for each attack in both cohorts.
IOS patients in Germany self-administer icatibant at a similar rate
Nearly all attacks treated with icatibant were treated by selfadministration in both Germany and other IOS countries (90.2% vs. 89.8%, respectively; P = 0.369).
IOS patients in Germany re-inject icatibant at a significantly lower rate
German patients reported approximately the same number of icatibant-treated attacks as their non-German counterparts; however, 97.1% of attacks in Germany were treated with a single icatibant injection, compared with 91.6% of attacks in other countries (P = 0.0003; Table 4 ). The use of rescue medication was not significantly different between German patients (138/ 576 attacks, 24.0%) and patients from other countries (654/4303 attacks, 15.2%; P = 0.138). However, of those attacks treated with rescue medication, IOS patients from Germany reported a significantly greater use of C1-INH concentrate (129/576 attacks, 22.4%) than patients from other IOS countries (325/4303 attacks; 7.6%; P < 0.001). Variation of C1-INH concentrate rescue use was also observed between German centres (Table 5 ). Of patients with available prophylaxis data, German patients (n = 20) reported different patterns of short-and long-term prophylaxis compared with patients in other IOS countries (n = 317; Fig. 4 ; overall P < 0.0001) with stanozolol, oxandrolone and tranexamic acid not utilized as prophylactic agents in IOS patients in Germany.
Discussion
This is the first report, using real-world IOS data, detailing the experience in Germany with icatibant for the acute treatment of HAE in adults and subsequent comparison with other IOS countries. These data build on a published report of the use of icatibant in a non-IOS, German HAE population from a large HAE specialist centre in Frankfurt. 16 That study, however, was published shortly after icatibant approval and derived from a single centre with limited data available at that time.
Overall, IOS patients in Germany were not different in terms of demographics or IOS entry characteristics from IOS patients in the other countries assessed. Delay in diagnosis for German patients, though numerically shorter than other countries, was not significantly shorter. These data suggest that while identification of HAE is certainly an improvement over the previously reported median delay in diagnosis of 8.5 years in past IOS analyses across the EU, 17 this delay is still unacceptably high. Beyond the bounds of HAE specialist care, delays in diagnosis are further confounded by the presenting clinical similarities between HAE and far more common conditions (e.g. appendicitis), which may not raise clinical suspicion of non-specialist HAE physicians.
11,18
Given the potential for fatal outcomes of laryngeal attacks, 3 the continuing effort to improve physician awareness of HAE is a clear priority.
The key finding of this analysis is that German patients treat their attacks with icatibant, regardless of severity, almost immediately upon recognition of symptoms. This would affirm German patient awareness and acceptance of physician recommendations based on the various evidence-based guidelines and consensus documents that promote treatment as early as possible. These data may even suggest growing patient confidence in management of their unpredictable disease. Treating so early may help explain why German patients reported significantly fewer severe or very severe attacks, as patients appear to treat rapidly and do not wait to see whether an attack will progress. There are, however, aspects of the German healthcare system, such as the level of reimbursement (100% for icatibant), 19, 20 and easier access to icatibant, that may, in part, explain how early treatment may be a simpler proposition for a patient with HAE within Germany compared with patients in other countries, where icatibant may be more difficult to obtain and doses perhaps retained for treatment of attacks that are deemed more severe. The comparable rate of icatibant self-administration across IOS countries has been described in other IOS studies and represents an acceptance by the HAE patient community of the longestablished advantage to the patient of rapid access to homebased acute therapy. 10, 21 That nearly all attacks in German IOS patients were treated with only a single icatibant injection is an important observation from both a patient and healthcare economic standpoint, though the administration of icatibant so soon after symptom onset may play a role in this outcome. The icatibant reinjection rate of approximately 10% in the other countries is reflective of the reinjection rate of approximately 10% reported in the randomized controlled clinical trial (FAST-2) 22 and prior IOS analyses. 10 The preference by some German patients to use C1-INH as both long-term and short-term prophylaxis and as a rescue medication is not surprising when viewed in the context of the long-standing experience of German HAE specialists with the use of C1-INH since 1979 for acute treatment of HAE. However, the relatively low numbers of German patients reporting C1-INH prophylaxis should be taken into account when interpreting the reduced severity of attacks in IOS patients in Germany.
Limitations of this analysis include the subjective nature of patient-reported attack severity and the nature of reporting realworld registry data, where data may not be complete for all outcomes in all instances. Another limitation is that standardized and validated tools to assess disease activity, impact and control were not used by all patients and not taken into account in this analysis. Instruments such as the angioedema activity score 23 and the Angioedema Quality of Life Questionnaire 24,25 should be used in future studies to better understand the impact of treatment on the course of HAE and attack features. 26 
Conclusion
Patients enrolled in IOS in Germany share similar demographic characteristics with patients from other IOS countries yet treat their attacks with icatibant significantly earlier and have markedly fewer severe or very severe attacks. Factors including C1-INH ongoing † long-term or short-term prophylaxis, n (%) regional access to and availability of icatibant may drive these outcomes and warrant further investigation.
